Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00369317 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
A Phase 3 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 205
- Enrollment target
NCT00369317 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 205 participants.
The verdict
NCT00369317, a Phase 3 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 205 participants
- Enrollment target
Study Summary
This phase III trial is studying how well combination chemotherapy works in treating young patients with Down syndrome and acute myeloid leukemia or myelodysplastic syndromes. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.
Interventions
- DRUG etoposide
- DRUG cytarabine
- DRUG asparaginase
- DRUG daunorubicin hydrochloride
- DRUG thioguanine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2007-03 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00369317
The ClinicalTrials.gov registry entry for NCT00369317 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which etoposide is the first listed.
NCT00369317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00369317 about?
NCT00369317 is a clinical study titled "Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes". This phase III trial is studying how well combination chemotherapy works in treating young patients with Down syndrome and acute myeloid leukemia or myelodysplastic syndromes. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stop...
What is the current status of trial NCT00369317?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 205 participants. The study started on 2007-03. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT00369317?
The interventions under investigation include: etoposide (DRUG), cytarabine (DRUG), asparaginase (DRUG), daunorubicin hydrochloride (DRUG), thioguanine (DRUG).
Who is sponsoring clinical trial NCT00369317?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.